Lord Abbett & CO. LLC Sells 105,239 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Lord Abbett & CO. LLC lessened its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 12.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 713,258 shares of the life sciences company’s stock after selling 105,239 shares during the period. Lord Abbett & CO. LLC owned about 0.92% of Integra LifeSciences worth $12,960,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of IART. CWM LLC grew its stake in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Integra LifeSciences by 24.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 12,929 shares of the life sciences company’s stock worth $377,000 after acquiring an additional 2,560 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth approximately $2,818,000. Blue Trust Inc. lifted its holdings in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Integra LifeSciences by 76.0% during the second quarter. Louisiana State Employees Retirement System now owns 34,500 shares of the life sciences company’s stock worth $1,005,000 after purchasing an additional 14,900 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.10% of the stock is owned by corporate insiders.

Integra LifeSciences Trading Down 0.9 %

Shares of IART opened at $24.03 on Monday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -267.00, a PEG ratio of 0.82 and a beta of 1.15. The business’s fifty day moving average is $22.12 and its 200-day moving average is $23.69.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the company posted $0.76 EPS. Equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on IART shares. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Truist Financial lowered their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Bank of America reduced their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and an average target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.